Search

everythinglearnresearchcommunity

for

Search:↓

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

The user started treating their slightly thinning, receded hairline with a serum containing Redensyl and other ingredients, and dermarolling weekly. They recently began taking finasteride and plan to stop Redensyl in the future to test if hair loss resumes.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

A user shared their 12-month progress using 0.5% Pyrilutamide once daily, 0.025% topical finasteride once daily, 5% Minoxidil twice daily, and microneedling 3 times a week. They reported good progress but noted a slowdown in recent months, hoping for thicker hair soon.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

A 30-year-old man shared his positive experience with hair regrowth using Regenera Activ, topical Dutasteride, Minoxidil, and PRP over 12 weeks. He plans to continue with injectable Dutasteride and emphasizes the importance of starting treatment early to combat hair loss.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

A user shared 3-month hair regrowth results using a combination of oral Dutasteride, daily Minoxidil, RU58841, micro-needling, Keto shampoo, scalp massages, and supplements. Positive progress was noted, and encouragement to continue was given.

A user is experiencing temple hair recession and is seeking alternatives to finasteride. They are considering castor oil, coconut oil, and derma rolling, and have seen some improvement with Zenegen.

Excess Vitamin A and topical retinoids can cause diffuse hair shedding. The user suspects their chronic telogen effluvium may be linked to using adapalene, a topical retinoid.

Using tretinoin, minoxidil, and The Ordinary Multi-Peptide Serum together for hair loss is discussed, with suggestions to skip the serum as it is ineffective for regrowth. Tretinoin is recommended for temple regrowth, and combining it with derma stamping is advised.

The conversation is about an 18-year-old male considering topical finasteride for hair loss and asking about the effectiveness of topical melatonin for hair regrowth and density. No specific treatments were confirmed to be used.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

The conversation discusses experimenting with microneedling for hair loss, with OP considering using a 3mm derma-stamp. Other users advise against going beyond 1.5mm to avoid damage.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

Using a topical formula with 5% minoxidil and 0.01% retinoic acid is considered effective, as tretinoin can enhance minoxidil results and improve scalp health.

Switching from tretinoin to tazarotene with minoxidil led to new hair regrowth after years of maintenance. Tazarotene's selectivity and higher concentration might be more effective for hair growth.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

Using tretinoin with minoxidil may improve absorption but results vary; some users see improved follicle growth while others notice no significant difference. Applying tretinoin before minoxidil is suggested by some users.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

A user shared their positive experience with Trichogenics for hair restoration, highlighting their unique zigzag hairline technique and personalized attention. They had 1700 follicles transplanted and praised the natural results.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The user had a hair transplant 10 months ago and sees some improvement but still has thin spots. They previously used finasteride pills and now use a topical solution of minoxidil, dutasteride, and tretinoin.